From Siga's Website:
Antiviral discovery assays are developed in the SIGA laboratory and then customized for use in screening our diverse chemical library of small molecules. Screening is carried out using multiple assays for each target pathogen, an approach aimed at identifying compounds of varied target specificity and mechanistic class. Candidate antiviral compound series are then optimized through iterative medicinal chemistry and preclinical assessment efforts at SIGA, followed by assessment of compound efficacy in proof-of-concept experiments using small animal models of target-virus disease. Screening results are catalogued in SIGA databases, allowing for identification of compounds with broad intra- or inter-virus family specificity.
Current discovery targets:
Influenza virus (H5N1, H2N1)
Bunyavirus (Rift Valley Fever virus, La Crosse virus)
Filovirus (Marburg virus, Ebola virus)
Flavivirus (West Nile virus)